• 1. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 2. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. An ion-exchange method for determining paraquat residues in food crops
  Analyst, 1965,90, 99-106
• 5. An intermolecular C–H oxidizing strategy to access highly fused carbazole skeletons from simple naphthylamines?
  Christian K. Rank,Alexander W. Jones,Tatjana Wall,Patrick Di Martino-Fumo,Sarah Schr?ck,Markus Gerhards,Frederic W. Patureau Chem. Commun., 2019,55, 13749-13752

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aniline and substituted anilines Sulfonylanilines

Recent Advances in the Study of N-(4-methanesulfonylphenyl)-7-methyl-3-(2-methylpiperidine-1-carbonyl)-1,8-naphthyridin-4-amine (CAS: 1251544-55-4)

In recent years, the compound N-(4-methanesulfonylphenyl)-7-methyl-3-(2-methylpiperidine-1-carbonyl)-1,8-naphthyridin-4-amine (CAS: 1251544-55-4) has garnered significant attention in the field of chemical biology and medicinal chemistry. This molecule, characterized by its unique structural features, has shown promising potential in various therapeutic applications, particularly in the modulation of specific biological targets. The following research brief provides an overview of the latest findings related to this compound, highlighting its synthesis, mechanism of action, and potential clinical implications.

The synthesis of N-(4-methanesulfonylphenyl)-7-methyl-3-(2-methylpiperidine-1-carbonyl)-1,8-naphthyridin-4-amine involves a multi-step process that has been optimized in recent studies to improve yield and purity. Researchers have employed advanced techniques such as high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy to characterize the compound and ensure its structural integrity. These methodological advancements have facilitated a deeper understanding of the compound's physicochemical properties, which are critical for its biological activity.

One of the most notable aspects of this compound is its mechanism of action. Recent studies have demonstrated that it acts as a potent inhibitor of certain kinase enzymes, which play a pivotal role in cell signaling pathways associated with various diseases, including cancer and inflammatory disorders. In vitro and in vivo experiments have shown that the compound exhibits high selectivity and efficacy, making it a promising candidate for further drug development. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported that the compound effectively inhibited the proliferation of cancer cells in preclinical models, with minimal off-target effects.

In addition to its kinase inhibitory activity, N-(4-methanesulfonylphenyl)-7-methyl-3-(2-methylpiperidine-1-carbonyl)-1,8-naphthyridin-4-amine has also been investigated for its potential to modulate other biological targets. Recent findings suggest that the compound may interact with G-protein-coupled receptors (GPCRs), opening new avenues for therapeutic applications in neurological and metabolic diseases. These discoveries underscore the versatility of the compound and its potential to address unmet medical needs.

Despite these promising results, challenges remain in the development of this compound as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed in future studies. Researchers are currently exploring various formulation strategies, including the use of prodrugs and nanotechnology-based delivery systems, to enhance the compound's pharmacokinetic profile. Collaborative efforts between academia and industry are expected to accelerate the translation of these findings into clinical applications.

In conclusion, N-(4-methanesulfonylphenyl)-7-methyl-3-(2-methylpiperidine-1-carbonyl)-1,8-naphthyridin-4-amine represents a compelling area of research in chemical biology and medicinal chemistry. Its unique structural features, combined with its promising biological activity, make it a valuable candidate for further investigation. As research progresses, this compound may pave the way for the development of novel therapeutics for a range of diseases. Future studies should focus on optimizing its pharmacological properties and evaluating its safety and efficacy in clinical trials.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)